Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of ...

A recent video produced by Vapourtec highlights the patented automatic Variable Bed Flow Reactor (VBFR) demonstrating fully automated solid phase peptide synthesis (SPPS).The process begins with ...

Edema is a medical condition characterized by the accumulation of excess fluid in the body’s tissues, leading to swelling and ...

The Interventional Oncology Market is poised for significant growth, projected to reach USD 3.9 billion by 2025, expanding at ...

Hiring the right Laravel development company is not just about technical skills. It's about finding a team that understands ...

Introduction: The Convergence of AI and Life SciencesTraditionally, drug discovery is a time-consuming and costly process, ...

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...

As we have highlighted in prior blog posts, the ability to augment design characteristics with custom R code is especially relevant to the ever-evolving therapeutic area of oncology. As regulatory ...

Results from Operations for first quarter 2025 versus first quarter last year:Revenue: $3.35 billion versus $3.18 billionDiluted EPS: $2.52 versus $2.69Adjusted EPS: $3.84 versus $3.68Reaffirmed ...

On the last day of February every year is Rare Disease Day, a dedicated day to celebrate the rare disease community, including patients, families, caregivers, clinicians, researchers, regulators, and ...

Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare ...

Effective July 1, 2025, he will succeed Oliver Rittgen who has decided to pursue a career opportunity outside of Bayer after 25 years with the company / Guru Ramamurthy has extensive expertise in ...